Get the Stockscreener App
5.74
1.77%
0.10
After Hours:
5.58
-0.16
-2.79%
Aardvark Therapeutics Inc stock is traded at $5.74, with a volume of 394.05K.
It is up +1.77% in the last 24 hours and down -49.16% over the past month.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
See More
Previous Close:
$5.64
Open:
$5.59
24h Volume:
394.05K
Relative Volume:
1.54
Market Cap:
$124.98M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-54.08%
1M Performance:
-49.16%
6M Performance:
-33.26%
1Y Performance:
-49.56%
1-Day Range:
$5.50
$5.99
1-Week Range:
$4.74
$12.68
52-Week Range:
$4.74
$17.94
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Name
Aardvark Therapeutics Inc
Sector
Industry
Phone
(858) 225-7696
Address
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
5.74 | 122.80M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | B. Riley Securities | Buy |
| Dec-23-25 | Initiated | Oppenheimer | Outperform |
| Dec-12-25 | Initiated | William Blair | Outperform |
| Dec-03-25 | Initiated | Raymond James | Strong Buy |
| Nov-07-25 | Initiated | BTIG Research | Buy |
| Sep-29-25 | Initiated | Stifel | Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Initiated | BofA Securities | Buy |
| Mar-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-10-25 | Initiated | Morgan Stanley | Overweight |
| Mar-10-25 | Initiated | RBC Capital Mkts | Outperform |
View All
Aardvark Therapeutics Inc Stock (AARD) Latest News
A Look At Aardvark Therapeutics (AARD) Valuation After HERO Trial Pause And Volatile Share Price Moves - simplywall.st
NOTICE TO DISREGARD -- Pomerantz LLP - GlobeNewswire Inc.
A Look At Aardvark Therapeutics (AARD) Valuation After The Voluntary Pause Of Its Phase 3 HERO Trial - Yahoo Finance
What's Going On With Aardvark Therapeutics Stock On Wednesday? - Bitget
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Aardvark Therapeutics (AARD) Is Down 61.4% After Pausing Phase 3 HERO Trial Over Cardiac Safety Questions - Yahoo Finance UK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - GlobeNewswire Inc.
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
Why AMTD Digital Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - Sahm
Dow Falls 150 Points; ISM Manufacturing PMI Edges Lower In February - Sahm
Twilio To Rally More Than 32%? Here Are 10 Top Analyst Forecasts For Monday - Sahm
This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Aardvark Therapeutics (AARD) Is Down 56.5% After Pausing Phase 3 HERO Trial for ARD-101 - simplywall.st
AARD Stock Sees Downgrade as RBC Capital Lowers Price Target | A - GuruFocus
Biotech Stock Crashes 50%-Plus. What Happened? - Investor's Business Daily
Aardvark Therapeutics Inc (AARD) Stock Price, Quote, News & History - Benzinga
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial - Stocktwits
Aardvark Therapeutics stock plunges after trial pause - Investing.com Nigeria
Aardvark Therapeutics stock plunges after trial pause By Investing.com - Investing.com UK
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
PWS phase III HERO’s journey stalled, Aardvark digs into data - bioworld.com
Oppenheimer Has Lowered Expectations for Aardvark Therapeutics (NASDAQ:AARD) Stock Price - MarketBeat
Aardvark Therapeutics, Chevron, Crowdstrike - TradingView
BofA cuts Aardvark Therapeutics stock price target on trial pause By Investing.com - Investing.com Canada
BofA cuts Aardvark Therapeutics stock price target on trial pause - Investing.com South Africa
Oppenheimer Adjusts Aardvark Therapeutics Price Target to $21 From $35, Maintains Outperform Rating - marketscreener.com
Stock Market Today: S&P 500, Dow, Nasdaq Futures Slide Amid US And Israel 'Operation Epic Furry' Against Iran— HKD, AARD, MDB In Focus (UPDATED) - Benzinga
AARD: Analyst BTIG Lowers Price Target, Maintains Buy Rating | A - GuruFocus
Stifel Nicolaus Downgrades Aardvark Therapeutics to Hold From Buy, Adjusts PT to $6 From $24 - marketscreener.com
HC Wainwright Downgrades Aardvark Therapeutics to Neutral From Buy - marketscreener.com
Aardvark Therapeutics (NASDAQ:AARD) Given New $9.00 Price Target at BTIG Research - MarketBeat
Aardvark Therapeutics (NASDAQ:AARD) Earns "Equal Weight" Rating from Morgan Stanley - MarketBeat
Aardvark Therapeutics' (AARD) "Hold" Rating Reiterated at Stifel Nicolaus - MarketBeat
HC Wainwright Reaffirms Neutral Rating for Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat
This Novo Nordisk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Aardvark’s PWS Trial Pause Raises Questions On Safety Edge For Appetite Suppressor - Citeline News & Insights
Aardvark Therapeutics stock price target cut to $9 by BTIG on trial pause - Investing.com Australia
RBC Downgrades Aardvark Therapeutics to Sector Perform From Outperform, Cuts Price Target to $6 From $18, Keeps Speculative Risk - marketscreener.com
Why Is Aardvark Therapeutics Stock Sinking Monday? - Bitget
Morgan Stanley Downgrades Aardvark Therapeutics to Equalweight From Overweight, Cuts Price Target to $7 From $29 - marketscreener.com
AARD Downgraded to Neutral by HC Wainwright & Co. | AARD Stock N - GuruFocus
Stifel Downgrades Aardvark Therapeutics (AARD) and Lowers Price Target | AARD Stock News - GuruFocus
Stifel cuts Aardvark Therapeutics stock rating on trial pause By Investing.com - Investing.com Canada
Morgan Stanley downgrades Aardvark Therapeutics stock rating on trial pause - Investing.com India
Stifel cuts Aardvark Therapeutics stock rating on trial pause - Investing.com
Crude Oil Rises Sharply; Sealed Air Posts Upbeat Earnings - Sahm
RBC Capital downgrades Aardvark Therapeutics stock rating on trial pause By Investing.com - Investing.com Canada
RBC Capital downgrades Aardvark Therapeutics stock rating on trial pause - Investing.com
Aardvark Therapeutics downgraded to Hold from Buy at Stifel - TipRanks
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm - lincolnjournal.com
Aardvark Therapeutics Inc Stock (AARD) Financials Data
There is no financial data for Aardvark Therapeutics Inc (AARD). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):